Parry M F, Neu H C
Am J Med. 1978 Jun;64(6):961-6. doi: 10.1016/0002-9343(78)90450-3.
The combination of ticarcillin plus tobramycin (TT) or carbenicillin plus gentamicin (CG) was used to treat 82 patients with severe systemic gram-negative infection in a prospective, randomized study. Pseudomonas aeruginosa was the primary pathogen in 7 (93 per cent) of these patients. Patients treated with TT responded more frequently (92 per cent or 37 of 40) than patients treated with CG (71 per cent or 30 of 42) (p is less than 0.05). This difference was primarily due to a greater response to TT in patients with pulmonary infections (93 per cent versus 68 per cent) and infections due to Pseudomonas (92 per cent versus 70 per cent). Severity of underlying disease was also an important determinant of response. Except for a greater incidence of hepatotoxicity with CG (23 per cent versus 3 per cent; p is less than 0.02), there was no difference in toxicity, colonization with drug-resistant microorganisms or superinfection between the two treatment groups. The combination of TT appears to be superior to CG for the treatment of pulmonary infections due to Pseudomonas aeruginosa.
在一项前瞻性随机研究中，使用替卡西林加妥布霉素（TT）或羧苄西林加庆大霉素（CG）联合治疗82例严重全身性革兰阴性菌感染患者。铜绿假单胞菌是其中7例（93%）患者的主要病原体。接受TT治疗的患者反应率（92%，即40例中的37例）高于接受CG治疗的患者（71%，即42例中的30例）（p<0.05）。这种差异主要是由于肺部感染患者（93%对68%）和铜绿假单胞菌感染患者（92%对70%）对TT的反应更好。基础疾病的严重程度也是反应的一个重要决定因素。除了CG的肝毒性发生率更高（23%对3%；p<0.02）外，两个治疗组在毒性、耐药微生物定植或二重感染方面没有差异。对于治疗铜绿假单胞菌引起的肺部感染，TT联合用药似乎优于CG联合用药。
